Syensqo (SYENS) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
19 Nov, 2025Executive summary
Q1 2025 net sales were €1.62 billion, flat year-over-year, with stable pricing and a 1% volume decline; sequential sales rose 1% due to higher pricing.
Composite Materials and Technology Solutions delivered double-digit growth, while Specialty Polymers declined due to electronics end-market weakness.
Underlying EBITDA was €311 million, down 15% year-over-year but up 5% sequentially, with a 19.2% margin.
Free cash flow was €37 million, impacted by capex phasing; operating cash flow was €176 million.
Share buyback program repurchased approximately 758,000 shares for €56 million, with about 40–50% of the €300 million program completed.
Financial highlights
Gross profit was €514 million, margin 31.7%, down 420 bps year-over-year but up 160 bps sequentially.
Underlying EBITDA margin was 19.2%, down 310 bps year-over-year, up 60 bps sequentially.
Net financial debt stood at €1.9 billion, leverage ratio at 1.4x, gearing at 22%.
Free cash flow was €37 million, down from €157 million year-over-year.
Cash and cash equivalents at quarter-end were €579 million.
Outlook and guidance
2025 outlook unchanged: underlying EBITDA at least €1.4 billion, capex ~€600 million, free cash flow ~€400 million.
Q2 2025 EBITDA expected to improve sequentially; H2 2025 anticipated to outperform H1, supported by Electronics and Civil Aviation.
Cost savings and restructuring underway, targeting €200 million run-rate savings by end of 2026 and ~200 position reductions.
Guidance excludes potential impacts from tariffs and FX volatility.
Latest events from Syensqo
- 2025 saw lower sales and profit but higher free cash flow; 2026 set for modest growth.SYENS
Q4 202526 Feb 2026 - Record financials, innovation, and bold sustainability targets defined the meeting.SYENS
AGM 20243 Feb 2026 - Q2 saw sequential growth but year-over-year declines, with CapEx delayed and cash flow hit by settlement.SYENS
Q2 20242 Feb 2026 - Q2 2025 sales and EBITDA fell YoY, but margin gains and stable 2025 outlook were maintained.SYENS
Q2 202521 Jan 2026 - Margins and cash flow held firm despite lower sales, with specialty focus and divestment ongoing.SYENS
Q3 202521 Jan 2026 - 2024 delivered strong cash flow and returns; 2025 targets stable EBITDA and strategic focus.SYENS
Q4 202421 Jan 2026 - Q3 2024 delivered organic growth, margin resilience, and a €300 million buyback launch.SYENS
Q3 202421 Jan 2026 - SSc and HS studies lead a robust pipeline, with major catalysts and data readouts expected in 2025–2026.SYENS
Piper Sandler 36th Annual Healthcare Conference12 Jan 2026 - Strong 2024 results, higher returns, and accelerated innovation amid global challenges.SYENS
AGM 202521 Nov 2025